CN1389266A - Ointment for treating burns and scalds and its prepn. - Google Patents
Ointment for treating burns and scalds and its prepn. Download PDFInfo
- Publication number
- CN1389266A CN1389266A CN 02135222 CN02135222A CN1389266A CN 1389266 A CN1389266 A CN 1389266A CN 02135222 CN02135222 CN 02135222 CN 02135222 A CN02135222 A CN 02135222A CN 1389266 A CN1389266 A CN 1389266A
- Authority
- CN
- China
- Prior art keywords
- parts
- ointment
- units
- interferon
- growth factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The composition of ointment for curing burn and scald comprises the following components (by weight portion) antibiotic 1-15, anisodamine 0.5-2, corticosteroid medicine 1-10, SOD 20-50, alpha-interferon 150-250 ten thousand unit, VE 1-20, epidermal growth factor 2-10 unit and ointment base 80-150. Its preparation method includes: heating and melting wool fat, vaseline, liquid paraffin wax and monostearin and using them as oil phase; heating and melting glycerin, octadecanol, distilled water and triethanolamine and using them as water phase; cooling water phase to below 60 deg.C, adding anixodamine, corticosteroid medicine and VE and uniformly mixing them, cooling to below 40 deg.C, adding SOD, interferon and epidermal growth factor, adding water phase into oil phase, uniformly stirring them and adding antibiotic; filling and cold-storing at below 10 deg.C. Its therapeutic effect is good.
Description
Technical field
The invention belongs to medicinal preparation, relate in particular to the ointment and preparation method thereof of the treatment burn of a kind of SOD of containing, alpha-interferon and epidermal growth factor.
Technical background
Clinically, treatment burn or use Western medicine ointment; Or use traditional Chinese herb medicine, as Granted publication CN104619C " ointment for burns and scalds "; Or with in, western bonded ointment, as Granted publication CN1058619C " a kind of antiphlogistic analgesic ointment for treating burn ", on Western medicine cephamycin and chloromycetin basis, increased antibiotic Chinese medicine Rhizoma Coptidis etc. again; Though curative effect is each has something to recommend him, all be compatibility in original antibiotic, anti-inflammation drugs category basically.
Summary of the invention
The objective of the invention is to introduce new technological achievement, look for another way.
Technical scheme of the present invention is: develop a kind of ointment for the treatment of burn, it is characterized in that mainly containing the component that following weight is formed: 80～150 parts in 1～15 part in antibiotic, 0.5～2 part of Anisodamine, 1～10 part of corticosteroids, 20～50 parts of superoxide dismutase, alpha-interferon 150～2,500,000 units, 1～20 part of vitamin E, epidermal growth factor 2～10 units, ointment base.
Or mainly contain the component that following weight is formed: 90～120 parts in 5～12 parts in antibiotic, 1～1.5 part of Anisodamine, 3～8 parts of corticosteroids, 10～40 parts of superoxide dismutase, alpha-interferon 180～2,200,000 units, 5～15 parts of vitamin Es, epidermal growth factor 6～8 units, ointment base;
Also can be mainly to contain the component that following weight is formed: 95～105 parts in 9～11 parts in antibiotic, 0.8～1.2 part of Anisodamine, 5～6 parts of corticosteroids, 20～30 parts of superoxide dismutase, alpha-interferon 190～2,100,000 units, 8～10 parts of vitamin Es, epidermal growth factor 4～6 units, ointment base;
Described antibiotic is meant chloromycetin, neomycin or chlortetracycline; Described corticosteroids is meant hydrocortisone, prednisone or betamethasone; In the described ointment base part, can be 10～50 parts of lanolines, 30～40 parts of glyceryl monostearates, 5～20 parts in vaseline, 60～100 parts of liquid paraffin, 45～55 parts of glycerol, 8～12 parts of octadecanol, 3.5～4.5 parts of triethanolamine, 750～850 parts of distilled water.
The preparation method of above-mentioned treatment burn ointment is: lanoline, vaseline, liquid paraffin and the glyceryl monostearate of dosage is heated to is molten into oil phase; Glycerol, octadecanol, distilled water and triethanolamine heat fused that other gets dosage are water; When water is cooled to below 60 ℃, add Anisodamine, corticosteroids and vitamin E one by one, mixing is cooled to the adding of back below 40 ℃ superoxide dismutase, alpha-interferon and epidermal growth factor; This water that is dissolved with above-mentioned material is added in the oil phase, behind the stirring and evenly mixing, add the antibiotic of porphyrize again, retrogradation is promptly gradually for mastic; By medicine requirement packing, storage below 10 ℃.
Thinking of the present invention is: in the burn wound healing process, diseased region fibroblast collagen synthesizes out-of-proportion increase, and the collagen excess deposition causes producing the burn and scald cicatrix.Therebetween, fibroblastic growth and decline have determined the order of severity of scar tissue behind the wound healing.
The burn wound repair is early stage, promptly takes effectively to suppress the collagen fiber hypertrophy, quickens collagen decomposition, and promotes method such as epithelial tissue growth, can significantly reduce the appearance of burn cicatrix.
The existence of wound surface foreign body, the appearance of infection play crucial effects to the hypertrophy of cicatrix; Bacteriogenic extracellular toxin during serious traumatic infection can impel that vascular smooth muscle shrinks, spasm, causes capillary blood flow retardance and local tissue ischemia necrosis, and a large amount of hydrolysis of histone influence wound repair speed.
In the component that the present invention selects for use, chloromycetin (Chloromycetin), neomycin (Neomycin) or chlortetracycline (Aurcomycin), be antibiotic commonly used, staphylococcus, escherichia coli, numerous Streptococcus and Bacillus proteus in interior most burn and scald common bacteria, there is therapeutical effect preferably.
The use of Anisodamine (Anisodamine) can be by partial blood vessel dilating effect, makes around the empyrosis wound surface inflammatory invade the profit band and is improved quickly, for the remaining epithelial regeneration of wound surface is created a favorable environment; Anisodamine can also alleviate in the wound repair process contraction of scar tissue by directly suppressing the contraction of myofibroblast in addition.
Hydrocortisone (Hydrocortisone), prednisone (Prednisone) or betamethasone (Betamethasone) isocortex steroid medicine, it is the choice drug that is used for the treatment of the proliferative cicatrix always, corticosteroids is except that being suppressed to the fibroblast proliferation according to the study, still can increase the activity of collagenase, quicken the decomposition of collagen.
A large amount of leukocyte are invaded profit in the burn and scald earlier damage tissue, by the electron transport oxygen supply generation oxygen-derived free radicals of the DPNH I oxidase on the leukocyte film with DPNH I, or by respiratory chain approach generation oxygen-derived free radicals, a large amount of generations of oxygen-derived free radicals increase relevant with cicatrix collagen resulting anomaly; Superoxide dismutase (SOD, Superoxided dismutase) reduces the effect that cicatrix generates by removing oxygen-derived free radicals effectively thereby reach.
Interferon (Interferon) has antitumor, antiviral effect, and interferon obviously is suppressed to fibrocellular schizogamy effect in addition simultaneously, and fibroblastic collagen synthesis capability is obviously reduced, and can obviously reduce the volume of cicatrix.
Epidermal growth factor (epidermal growth factor) can significantly improve the epithelial hypertrophy speed of burn wound surface, shortens wound healing time.
Vitamin E is used for treatment exudative or that inflammatory skin is sick clinically already.
The clinic trial situation:
One, treatment group is with treatment burn ointment of the present invention agent (clinic trial name: " comfort scar rather frost "),
Two, treatment patient 70 examples, the oldest 56 years old; Minimum 3 years old; Male's 56 examples; Women's 14 examples.
In the case, dark II degree empyrosis wound surface 27 examples are distributed as: upper limb 10 examples, and lower limb 13 examples, trunk 4 examples, natural law 19.4 ± 3.7 days on average heals; Shallow III degree empyrosis wound surface 43 examples are distributed as: upper limb 6 examples, and lower limb 9 examples, trunk 28 examples, natural law 30.5 ± 4.6 days on average heals.
Three, the commercially available conventional medicine of matched group, trade name " zicao soft plaster ", 77 person-times of treatment patients, the oldest 56 years old; Minimum 3 years old; Male's 56 examples; Women's 14 examples.
In the case, dark II degree wound surface 35 examples are distributed as: upper limb 14 examples, and lower limb 17 examples, trunk 4 examples, natural law 18.4 ± 3.1 days on average heals; Shallow III degree empyrosis wound surface 42 examples are distributed as: upper limb 8 examples, and lower limb 10 examples, trunk 24 examples, natural law 32.9 ± 5.1 days on average heals.
Above data are learned by statistics and are handled p＞0.01, illustrate that difference is not remarkable on two kinds of medicine wound healing times.Can be used as the burn treating external used medicine so " comfort rather frost of scar ".
In addition, measure the empyrosis wound surface prognosis area that scabs, find that with ultrasonic measurement wound surface cicatrix hardness comfort the peaceful white medicine group of scar, it is light than the Oleum Radix Arnebiae (Oleum Radix Lithospermi) matched group that cicatrix generates degree through schedule method.
Four, clinical conclusion: treatment group and matched group compare, and wound healing natural law there was no significant difference (p＞0.01) illustrates that difference is not remarkable on two kinds of medicine wound healing times.Can be used as the burn treating external used medicine so " comfort rather frost of scar ".
Five, advantage of the present invention is: select advanced technological means such as superoxide dismutase, interferon and epidermal growth factor for use, scar hyperplasia area and thickness obviously alleviate than the matched group of conventional therapy.
The specific embodiment
Embodiment 1
Dosage: 150 parts of 50 parts in 15 parts in chloromycetin, 2 parts of Anisodamine, 10 parts of hydrocortisone, SOD (do not comprise and preserve substrate), alpha-interferon 2,500,000 units, 20 parts of vitamin Es, epidermal growth factor 10 units, ointment bases.With the application's method preparation treatment burn ointment; Because of containing biological product, need cold preservation to store, now with the current, best results.
Raw material sources: chloromycetin (Wuhan Pharmaceutical Factory), Anisodamine (Jinhu County, Jiangsu pharmaceutical factory) hydrocortisone (Shandong Xinhua Pharmaceutical Factory), SOD (Wuhan biological preparation institute), alpha-interferon 250 (Shenzhen Kexing Biological Products Co., Ltd), vitamin E (Zhejiang Ningbo-Hangzhou pharmaceutical factory), epidermal growth factor (Wuhan biological preparation institute); Ointment base is the commercially available prod.
Adopt aforementioned preparation method, make trial product and " comfort rather frost of scar ", try out in clinical.
Clinical results, therapeutic process and curative effect all meet theory and thinking that present patent application proposes.
Embodiment 2
Dosage: 80 parts in 1 part in chloromycetin, 0.5 part of Anisodamine, 1 part of hydrocortisone, 20 parts of SOD, alpha-interferon 1,500,000 units, 1 part of vitamin E, epidermal growth factor 2 units, ointment base.All the other are with embodiment 1.
Embodiment 3
Dosage: 130 parts in 8 parts in chloromycetin, 1 part of Anisodamine, 5 parts of hydrocortisone, 25 parts of SOD, alpha-interferon 2,000,000 units, 5 parts of vitamin Es, epidermal growth factor 5 units, ointment base.All the other are with embodiment 1.
Embodiment 4
Dosage: 90 parts in 5 parts in chloromycetin, 1.5 parts of Anisodamine, 3 parts of hydrocortisone, 18 parts of SOD, alpha-interferon 1,800,000 units, 5 parts of vitamin Es, epidermal growth factor 6 units, ointment base.All the other are with embodiment 1.
Embodiment 5
Dosage: 120 parts in 12 parts in chloromycetin, 1 part of Anisodamine, 8 parts of hydrocortisone, 21 parts of SOD, alpha-interferon 2,200,000 units, 15 parts of vitamin Es, epidermal growth factor 8 units, ointment base.All the other are with embodiment 1.
Embodiment 6
Dosage: 95 parts in 9 parts in chloromycetin, 0.8 part of Anisodamine, 5 parts of hydrocortisone, 19 parts of SOD, alpha-interferon 1,900,000 units, 8 parts of vitamin Es, epidermal growth factor 4 units, ointment base.All the other are with embodiment 1.
Embodiment 7
Dosage: 105 parts in 11 parts in chloromycetin, 1.2 parts of Anisodamine, 8 parts of hydrocortisone, 19 parts of SOD, alpha-interferon 2,200,000 units, 10 parts of vitamin Es, epidermal growth factor 6 units, ointment base.All the other are with embodiment 1.
Embodiment 8
Dosage: 150 parts of 15 parts of neomycin, 2 parts of Anisodamine, 10 parts of prednisones, 50 parts of SOD, alpha-interferon 2,500,000 units, 20 parts of vitamin Es, epidermal growth factor 10 units, ointment base.With the application's method preparation treatment burn ointment.
Clinical results, therapeutic process and curative effect all meet theory and thinking that present patent application proposes.
Embodiment 9
Dosage: 80 parts of 1 part of neomycin, 0.5 part of Anisodamine, 1 part of prednisone, 20 parts of SOD, alpha-interferon 1,500,000 units, 1 part of vitamin E, epidermal growth factor 2 units, ointment base.All the other are with embodiment 8.
Embodiment 10
Dosage: 130 parts of 8 parts of neomycin, 1 part of Anisodamine, 5 parts of prednisones, 25 parts of SOD, alpha-interferon 2,000,000 units, 5 parts of vitamin Es, epidermal growth factor 5 units, ointment base.All the other are with embodiment 8.
Embodiment 11
Dosage: 90 parts of 5 parts of neomycin, 1.5 parts of Anisodamine, 3 parts of prednisones, 18 parts of SOD, alpha-interferon 1,800,000 units, 5 parts of vitamin Es, epidermal growth factor 6 units, ointment base.All the other are with embodiment 8.
Embodiment 12
Dosage: 120 parts of 12 parts of neomycin, 1 part of Anisodamine, 8 parts of prednisones, 21 parts of SOD, alpha-interferon 2,200,000 units, 15 parts of vitamin Es, epidermal growth factor 8 units, ointment base.All the other are with embodiment 8.
Embodiment 13
Dosage: 95 parts of 9 parts of neomycin, 0.8 part of Anisodamine, 5 parts of prednisones, 19 parts of SOD, alpha-interferon 1,900,000 units, 8 parts of vitamin Es, epidermal growth factor 4 units, ointment base.All the other are with embodiment 8.
Embodiment 14
Dosage: 105 parts of 11 parts of neomycin, 1.2 parts of Anisodamine, 8 parts of prednisones, 19 parts of SOD, alpha-interferon 2,200,000 units, 10 parts of vitamin Es, epidermal growth factor 6 units, ointment base.All the other are with embodiment 8.
Embodiment 15
Dosage: 150 parts in 15 parts in chlortetracycline, 2 parts of Anisodamine, 10 parts of Anflogistos, 50 parts of SOD, alpha-interferon 2,500,000 units, 20 parts of vitamin Es, epidermal growth factor 10 units, ointment base.With the application's method preparation treatment burn ointment.
Clinical results, therapeutic process and curative effect all meet theory and thinking that present patent application proposes.
Embodiment 16
Dosage: 80 parts in 1 part in chlortetracycline, 0.5 part of Anisodamine, 1 part of Anflogisto, 20 parts of SOD, alpha-interferon 1,500,000 units, 1 part of vitamin E, epidermal growth factor 2 units, ointment base.All the other are with embodiment 15.
Embodiment 17
Dosage: 130 parts in 8 parts in chlortetracycline, 1 part of Anisodamine, 5 parts of Anflogistos, 25 parts of SOD, alpha-interferon 2,000,000 units, 5 parts of vitamin Es, epidermal growth factor 5 units, ointment base.All the other are with embodiment 15.
Embodiment 18
Dosage: 90 parts in 5 parts in chlortetracycline, 1.5 parts of Anisodamine, 3 parts of Anflogistos, 18 parts of SOD, alpha-interferon 1,800,000 units, 5 parts of vitamin Es, epidermal growth factor 6 units, ointment base.All the other are with embodiment 15.
Embodiment 19
Dosage: 120 parts in 12 parts in chlortetracycline, 1 part of Anisodamine, 8 parts of Anflogistos, 21 parts of SOD, alpha-interferon 2,200,000 units, 15 parts of vitamin Es, epidermal growth factor 8 units, ointment base.All the other are with embodiment 15.
Embodiment 20
Dosage: 95 parts in 9 parts in chlortetracycline, 0.8 part of Anisodamine, 5 parts of Anflogistos, 19 parts of SOD, alpha-interferon 1,900,000 units, 8 parts of vitamin Es, epidermal growth factor 4 units, ointment base.All the other are with embodiment 15.
Embodiment 21
Dosage: 105 parts in 11 parts in chlortetracycline, 1.2 parts of Anisodamine, 8 parts of Anflogistos, 19 parts of SOD, alpha-interferon 2,200,000 units, 10 parts of vitamin Es, epidermal growth factor 6 units, ointment base.All the other are with embodiment 15.
Claims (7)
1. ointment for the treatment of burn is characterized in that mainly containing the component that following weight is formed: 80～150 parts in 1～15 part in antibiotic, 0.5～2 part of Anisodamine, 1～10 part of corticosteroids, 20～50 parts of superoxide dismutase, alpha-interferon 150～2,500,000 units, 1～20 part of vitamin E, epidermal growth factor 2～10 units, ointment base.
2. according to the ointment of the described treatment burn of claim 1, it is characterized in that mainly containing the component that following weight is formed: 90～120 parts in 5～12 parts in antibiotic, 1～1.5 part of Anisodamine, 3～8 parts of corticosteroids, 10～40 parts of superoxide dismutase, alpha-interferon 180～2,200,000 units, 5～15 parts of vitamin Es, epidermal growth factor 6～8 units, ointment base.
3. according to the ointment of the described treatment burn of claim 1, it is characterized in that mainly containing the component that following weight is formed: 95～105 parts in 9～11 parts in antibiotic, 0.8～1.2 part of Anisodamine, 5～6 parts of corticosteroids, 20～30 parts of superoxide dismutase, alpha-interferon 190～2,100,000 units, 8～10 parts of vitamin Es, epidermal growth factor 4～6 units, ointment base.
4. according to the ointment of claim 1,2 or 3 described treatment burns, it is characterized in that antibiotic is meant chloromycetin, neomycin or chlortetracycline.
5. according to the ointment of claim 1,2 or 3 described treatment burns, it is characterized in that corticosteroids is meant hydrocortisone, prednisone or betamethasone.
6. according to the ointment of claim 1,2 or 3 described treatment burns, it is characterized in that to be 10～50 parts of lanolines, 30～40 parts of glyceryl monostearates, 5～20 parts in vaseline, 60～100 parts of liquid paraffin, 45～55 parts of glycerol, 8～12 parts of octadecanol, 3.5～4.5 parts of triethanolamine, 750～850 parts of distilled water in the ointment base part.
7. according to the preparation method of claim 1,2 or 3 described treatment burn ointments, it is characterized in that lanoline, vaseline, liquid paraffin and glyceryl monostearate with dosage is heated to be molten into oil phase; Glycerol, octadecanol, distilled water and triethanolamine heat fused that other gets dosage are water; When water is cooled to below 60 ℃, add Anisodamine, corticosteroids and vitamin E one by one, mixing is cooled to the adding of back below 40 ℃ superoxide dismutase, alpha-interferon and epidermal growth factor; This water that is dissolved with above-mentioned material is added in the oil phase, behind the stirring and evenly mixing, add the antibiotic of porphyrize again, retrogradation is promptly gradually for mastic; By medicine requirement packing, storage below 10 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02135222 CN1389266A (en) | 2002-06-18 | 2002-06-18 | Ointment for treating burns and scalds and its prepn. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02135222 CN1389266A (en) | 2002-06-18 | 2002-06-18 | Ointment for treating burns and scalds and its prepn. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1389266A true CN1389266A (en) | 2003-01-08 |
Family
ID=4748075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02135222 Pending CN1389266A (en) | 2002-06-18 | 2002-06-18 | Ointment for treating burns and scalds and its prepn. |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1389266A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103110627A (en) * | 2011-11-16 | 2013-05-22 | 高尔医药科技(上海)有限公司 | Application of medicinal composition |
| CN104997790A (en) * | 2015-07-29 | 2015-10-28 | 魏传梅 | Compound skin cream for treating leucoderma |
| CN105561312A (en) * | 2016-01-18 | 2016-05-11 | 张晓燕 | Western medicine composition for preventing and treating scalds |
| CN113230274A (en) * | 2021-05-28 | 2021-08-10 | 宁波市第一医院 | Scar-removing ointment and preparation method thereof |
| CN113368135A (en) * | 2021-05-28 | 2021-09-10 | 宁波市第一医院 | Scar-removing ointment based on extracellular matrix and preparation method thereof |
-
2002
- 2002-06-18 CN CN 02135222 patent/CN1389266A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103110627A (en) * | 2011-11-16 | 2013-05-22 | 高尔医药科技(上海)有限公司 | Application of medicinal composition |
| CN103110627B (en) * | 2011-11-16 | 2016-05-25 | 高尔医药科技(上海)有限公司 | A kind of application of pharmaceutical composition |
| CN104997790A (en) * | 2015-07-29 | 2015-10-28 | 魏传梅 | Compound skin cream for treating leucoderma |
| CN104997790B (en) * | 2015-07-29 | 2018-12-14 | 魏传梅 | A kind of compound skin cream for treating leucoderma |
| CN105561312A (en) * | 2016-01-18 | 2016-05-11 | 张晓燕 | Western medicine composition for preventing and treating scalds |
| CN113230274A (en) * | 2021-05-28 | 2021-08-10 | 宁波市第一医院 | Scar-removing ointment and preparation method thereof |
| CN113368135A (en) * | 2021-05-28 | 2021-09-10 | 宁波市第一医院 | Scar-removing ointment based on extracellular matrix and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1733294A (en) | Recombined human alkaline fibroblast growth factor gelling agent and process for preparing the same | |
| CN1289137C (en) | Medicine for treating mammary gland proliferation, its preparation method and application | |
| CN1911279A (en) | Acupuncture point plaster for preventing and treating bronchitic asthma and its prepn. method | |
| CN1070574A (en) | Low molecular weight vegetable composition | |
| CN1389266A (en) | Ointment for treating burns and scalds and its prepn. | |
| CN1270746C (en) | Medicine for diminishing the inflammation and reducing the pain, subsiding swelling to dissipate indurated mass, dredging meridian to removing stagnation | |
| CN111759896A (en) | Pharmaceutical application of total triterpene of pawpaw | |
| CN1262303C (en) | Mastitis treating medicine | |
| CN1259087C (en) | Medicine for treating trauma and sores and its preparing process | |
| CN1476845A (en) | Chinese medicine sanjieruxiao ointment and its preparation method | |
| CN1733147A (en) | Chinese traditional medicine for curing soft tissue pains and process for preparing the same | |
| CN108635362B (en) | Pharmaceutical composition for treating diabetic foot | |
| Weitman et al. | Copper dressings to the wound rescue after everything else failed: case report | |
| CN1251711C (en) | External use anti-inflammatory and myogenic medicine of chinese medicine and its preparing method | |
| CN115040501B (en) | Application of cis-13-octadecenoic acid or salt compound thereof in preparation of drugs for promoting healing of damaged skin and/or mucous membrane | |
| CN1136864C (en) | Chinese medicine for treating mastoproliferation | |
| CN1241629C (en) | External use medicine for treating AIDS virus | |
| CN1313117C (en) | Chinese medicine external applied powder for bone damage | |
| CN1189193C (en) | Ointment for treating burn | |
| CN1291704C (en) | Plaster design for post-operation incision | |
| CN1236798C (en) | External medicine for treating bone tuberculosis | |
| CN1298371C (en) | Medicine for treating hyperplasia of mammary glands and preparation method thereof | |
| CN102028909A (en) | Fumigant for treating parapsoriasis guttata | |
| CN1189200C (en) | Ointment for treating burn and scald | |
| CN1788790A (en) | Extrasin beta-16 for promoting vascularization, tissue regeneration and wound healing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |